research use only
Cat.No.S3957
| Related Targets | HDAC JAK BET Histone Methyltransferase PKC PARP HIF PRMT EZH2 AMPK |
|---|---|
| Other DNA Methyltransferase Inhibitors | RG108 SGI-1027 Zebularine (NSC 309132) GSK3685032 CM272 β-thujaplicin Bobcat339 DC-05 2'-Deoxy-5-Fluorocytidine GSK-3484862 |
| Molecular Weight | 602.89 | Formula | C40H58O4 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 11042-64-1 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | CC(CCC=C(C)C)C1CCC2(C1(CCC34C2CCC5C3(C4)CCC(C5(C)C)OC(=O)C=CC6=CC(=C(C=C6)O)OC)C)C | ||
|
In vitro |
DMSO
: 100 mg/mL
(165.86 mM)
|
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
| In vitro |
From the proliferation assay using MTT reagent, the effect of Gamma-Oryzanol on DU145 and PC3 are slightly different with an IC50 after 7 days of exposure at 0.52±0.06 and 0.40±0.08 mg/ml, respectively. For in vitro conditions in proliferation assay, IC50 values seem to be high in the scale of mg/ml. Gamma-Oryzanol may affect prostate cancer cells through the down regulation of some antioxidant genes, CAT and GPX.
|
|---|---|
| In vivo |
In tumour-bearing mice, Gamma-Oryzanol can reduce tumour mass associated with pro-angiogenic biomarkers. Gamma-Oryzanol is not carcinogenic and is safe for animals. In vivo trials proved Gamma-Oryzanol to be a powerful antioxidant and also appears to be a very promising anticancerogenic compound. Supplementation of Gamma-Oryzanol in diabetic patients may improve metabolic dysfunctions such as hyperglycaemia, hypercholesterolaemia, hypertriglyceridaemia, insulin resistance and may alleviate diabetic complications resulting from lipid peroxidation and free radicals.
|
References |
|
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.